PTC Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of orally-administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company's lead product, Translarna, is used for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis, Translarna for mucopolysaccharidosis type I caused by nonsense mutation, Translarna for nonsense mutation aniridia, and Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy in collaboration with Spinal Muscular Atrophy Foundation.
Type
Public
HQ
South Plainfield, US
Founded
1998
Size (employees)
304 (est)+3%
Website
ptcbio.com
PTC Therapeutics was founded in 1998 and is headquartered in South Plainfield, US
Report incorrect company information

Key People/Management at PTC Therapeutics

Stuart Peltz

Stuart Peltz

Chief Executive Officer
Marcio Souza

Marcio Souza

Chief Operating Officer
Mark Boulding

Mark Boulding

Executive Vice President and Chief Legal Officer
Mary Harmon

Mary Harmon

Senior Vice President, Corporate Relations
Martin Rexroad

Martin Rexroad

Senior Vice President, Human Resources
Megan Sniecinski

Megan Sniecinski

Senior Vice President, Business Operations and Program Management
Show more

PTC Therapeutics Office Locations

PTC Therapeutics has an office in South Plainfield
South Plainfield, US (HQ)
100 Corporate Ct
Show all (1)
Report incorrect company information

PTC Therapeutics Financials and Metrics

PTC Therapeutics Financials

PTC Therapeutics's revenue was reported to be $194.39 m in FY, 2017
USD

Revenue (Q1, 2018)

56.1 m

EBIT (Q1, 2018)

(16.7 m)

Market capitalization (15-May-2018)

1.4 b

Closing share price (15-May-2018)

30

Cash (31-Mar-2018)

97.7 m

EV

1.4 b
PTC Therapeutics's current market capitalization is $1.4 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

34.7 m25.2 m36.8 m82.7 m194.4 m

Revenue growth, %

(27%)46%125%

General and administrative expense

121.3 m

R&D expense

117.5 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

9.2 m1.7 m1.7 m7.5 m6.8 m9.8 m18.9 m15.6 m23 m26.5 m48 m56.1 m

Cost of goods sold

39 k758 k

Gross profit

26.5 m47.2 m

Gross profit Margin, %

100%98%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

15.4 m49.7 m58 m58.3 m111.8 m

Accounts Receivable

11.1 m24.9 m40.4 m

Inventories

1.6 m3.9 m5.9 m4.7 m10.8 m

Current Assets

145 m323.6 m355.9 m261.3 m249.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

24 m115.9 m21.2 m52.9 m36.8 m29.2 m140.7 m40.2 m35.7 m50.3 m54.1 m133 m97.7 m

Accounts Receivable

22.6 m19.8 m27.4 m32.2 m33.8 m45.6 m

Inventories

1.4 m6.9 m12.4 m

Current Assets

160.1 m249.4 m230.3 m213.5 m289.8 m264.6 m384.2 m326.4 m297.4 m280.6 m240.7 m227 m242 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(51.6 m)(93.8 m)(170.4 m)(142.1 m)(79 m)

Depreciation and Amortization

2.4 m2.2 m2.9 m3.3 m17.7 m

Inventories

(760.5 k)(2.3 m)(2.1 m)1.2 m

Accounts Payable

5.2 m16.9 m17 m4.3 m24 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(33.7 m)(14.1 m)(39.2 m)(66.5 m)(37.9 m)(76.3 m)(119.5 m)(41.2 m)(80.1 m)(115.3 m)(29.1 m)(46.5 m)(19.3 m)

Depreciation and Amortization

1.8 m588 k1.2 m1.7 m634 k1.3 m2.1 m849 k1.7 m2.5 m612 k1.4 m6 m

Inventories

(1.4 m)

Accounts Payable

3.2 m(3.5 m)(866 k)4.3 m(5.6 m)(6 m)2.9 m(2.5 m)(3.4 m)2.1 m(3.9 m)12.5 m(6.8 m)
USDY, 2018

EV/EBIT

-86.2 x

EV/CFO

-90.9 x

Financial Leverage

2.5 x
Show all financial metrics
Report incorrect company information